Q-omics provides the consensus-scored PDE3B profile across patient tissues and cancer cell-line models. PDE3B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PDE3B is differentially expressed in 13, with the highest sampling consensus in STAD. Additionally, PDE3B RNA expression shows 19,673 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, STAD, and TGCT as cancer lineages where PDE3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE3B survival associations across molecular data types. PDE3B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE3B RNA expression–survival associations across cancer types. High PDE3B expression shows unfavorable associations in ACC, KIRP and UCEC, but favorable associations in HNSC, PAAD and LAML. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PDE3B RNA expression.
This table summarizes PDE3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in STAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PDE3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE3B shows lower tumor expression in BRCA, LUAD, BLCA, LUSC and KIRC and higher tumor expression in STAD. The STAD box plot shows higher PDE3B RNA expression in tumor versus normal tissue (log2 FC = +0.882, t-test p < 0.001).
This table shows molecular features associated with PDE3B in patient tissues and cancer cell lines. In patient samples, PDE3B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
